Tirzepatide Weight Loss: The Trial Evidence

The short version

The tirzepatide weight loss trials — known as the SURMOUNT programme — are the largest and most comprehensive randomized controlled trials of any weight-loss medicine to date. The headline number is -20.9%: that is the average percentage of body weight lost by adults taking the 15 mg dose over 72 weeks, compared with -3.1% on placebo. That translates to roughly 52 lbs of weight lost in a person starting at 250 lbs. In a direct comparison against another weight-loss medicine (semaglutide), tirzepatide produced about 6.5 percentage points more weight loss. Most side effects are digestive — nausea, constipation, upset stomach — and are worst during the first few weeks of each dose increase. This page covers what the trials measured, how the weight was lost, how quality of life changed, and what the evidence says about plateaus and weight regain after stopping.

SURMOUNT-1: The core obesity trial

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI of 30 or above, or 27 or above with a weight-related complication such as high blood pressure, high cholesterol, or obstructive sleep apnea) and without type 2 diabetes. Participants received once-weekly subcutaneous tirzepatide at 5, 10, or 15 mg or placebo, with a 20-week stepwise dose escalation (starting at 2.5 mg), and were followed for 72 weeks ^[4].

Mean weight changes at week 72: -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo ^[4]. The proportion of participants achieving at least 5% weight loss was 85% (5 mg), 89% (10 mg), and 91% (15 mg) versus 35% with placebo. At least 20% weight loss — a threshold rarely reached in prior drug trials — was achieved by 50% of the 15 mg group ^[4].

The tirzepatide results scale: 15 mg produced roughly a 7-fold greater proportional weight loss than placebo. For context, prior selective GLP-1 receptor agonists had produced mean reductions of approximately 14-17% in comparable populations at their maximum doses. Tirzepatide's 15 mg result sits at the high end of that range and, in the SURMOUNT-5 head-to-head, significantly exceeded it ^[5].

The most common adverse events were gastrointestinal and mostly mild to moderate: nausea, diarrhea, vomiting, and constipation occurred primarily during dose escalation and declined thereafter ^[4]. Discontinuation due to adverse events was 4.3-7.4% across the three doses versus 2.6% with placebo ^[4].

For data on tirzepatide results across the full programme, the network meta-analysis by Pan XH et al. (2024) evaluated 31 RCTs enrolling more than 35,000 participants and found tirzepatide 15 mg ranked in the top three across weight-related outcomes and achieved the highest efficacy for reaching at least 15% weight loss versus placebo (risk ratio 10.24, 95% CI 6.42-16.34) ^[8].

Tirzepatide vs semaglutide

The direct head-to-head comparison came in SURMOUNT-5, a phase 3b open-label trial in 751 adults with obesity but without type 2 diabetes. Participants were randomized to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg) for 72 weeks ^[5].

Least-squares mean weight change at 72 weeks: -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001). Tirzepatide also produced a greater reduction in waist circumference and higher proportions reaching 10%, 15%, 20%, and 25% weight loss thresholds ^[5].

In type 2 diabetes, SURPASS-2 (40 weeks, 1,879 participants) had earlier established tirzepatide's glycemic and weight superiority versus semaglutide 1 mg: HbA1c reductions of 2.01-2.30 percentage points with tirzepatide versus 1.86 with semaglutide, and weight treatment differences of -1.9 to -5.5 kg ^[3]. The SURMOUNT-5 data extended that superiority to the obesity-without-diabetes indication, making the comparative picture consistent across both populations.

It is worth noting that both trials were open-label (participants and investigators knew which treatment was assigned), which is a methodological limitation for patient-reported outcomes, though objective weight is less susceptible to unblinding effects than subjective endpoints.

Tirzepatide results: quality of life and time to plateau

Weight loss without improved quality of life is an incomplete picture. A post hoc analysis of SURMOUNT-1 patient-reported outcomes found that greater weight reduction tracked consistently with larger health-related quality-of-life improvements: the incremental trend began from at least 5% weight reduction, with the largest gains at 20% or more weight loss ^[10]. Participants with baseline physical or psychosocial limitations showed the steepest improvements. SF-36v2 Physical Component Summary scores and the IWQOL-Lite-CT (a weight-related quality-of-life instrument) both improved in proportion to weight lost ^[10].

A separate post hoc analysis of SURMOUNT-1 and SURMOUNT-4 examined the time course of weight loss: most participants reached a weight plateau by about week 72 ^[11]. Higher doses, younger age, and female sex were associated with a longer time to plateau — that is, these groups continued losing weight for longer before weight stabilized ^[11]. Understanding the plateau timing matters for managing expectations: a period of stable weight after 18 months of treatment is a predictable part of the drug's kinetics, not necessarily treatment failure.

A 2025 post hoc cardiometabolic analysis of SURMOUNT-1 (n=1,605) found progressive improvements in systolic blood pressure, waist circumference, HOMA-IR (a marker of insulin resistance), and HbA1c across weight-loss categories. Among participants losing at least 35% of body weight: systolic BP changed by -14.2 mmHg, waist circumference by -32.4 cm, HOMA-IR by -59.7% ^[15].

Weight after stopping tirzepatide

The SURMOUNT-4 trial directly addressed what happens after treatment ends. Participants who had already lost weight on tirzepatide were rerandomized to continue tirzepatide or switch to placebo. Those who continued tirzepatide lost additional weight; those switched to placebo regained an average of approximately 14% of body weight from baseline over the following 52 weeks — effectively reversing much of the initial loss ^[19].

A 2026 JAMA Internal Medicine analysis of cardiometabolic parameters during regain found that improvements in blood pressure, lipids, and glycemia tracked with weight regain after stopping — the metabolic benefits were not durably maintained in the absence of continued treatment ^[20]. Pooled discontinuation data across semaglutide and tirzepatide trials estimated a mean weight regain of roughly 9.7 kg after stopping, consistent with the mechanism: the drug suppresses appetite while present, and appetite returns when it is cleared ^[18].

This evidence frames tirzepatide as a chronic therapy rather than a short-course intervention. Whether ongoing treatment is appropriate for a given person is a clinical question outside the scope of this editorial digest.